{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Escude Martinez de Castilla P"],"funding":["Fondation ARC pour la Recherche sur le Cancer","Agence Nationale de la Recherche","Horizon 2020","Fondation pour la Recherche Médicale","HORIZON EUROPE Marie Sklodowska-Curie Actions"],"pagination":["e2500605"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12447046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(24)"],"pubmed_abstract":["Prostate cancer (PCa) ranks as the fifth leading cause of cancer-related deaths among men worldwide. In 10-20% of the cases, PCa progresses to an incurable, castration-resistant stage. Castration-resistant PCa cells often overexpress prostate-specific membrane antigen (PSMA), a membrane protein that may serve as their Achilles' heel. Over the past decades, RNA-based therapeutics have emerged as promising treatments for a vast array of diseases, including cancer. In this study, with the ultimate goal of developing a targeted therapy for PCa, lipid nanoparticles (LNPs) are decorated with an anti-PSMA nanobody using click chemistry with a PEG-lipid. Direct stochastic optical reconstruction microscopy (dSTORM) and cluster analysis confirm the presence of at least one nanobody on the surface of"],"journal":["Advanced healthcare materials"],"pubmed_title":["Nanobody-Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo."],"pmcid":["PMC12447046"],"funding_grant_id":["ANR-20-CE18-0026-0","ANR‐20‐CE18‐0026‐0","860303","825828","ARCDOC42022010004513","PGA1 RF20190208474","AJE20160635884"],"pubmed_authors":["Escude Martinez de Castilla P","van Niel G","van Weerden WM","van Royen ME","Kooijmans SAA","Fens MH","Rietveld J","Schiffelers RM","Jenster G","Verdi V","van Kempen S","Vader P","Koekman AC","Yang Q","Estape Senti M","de Voogt W","van Merris J"],"additional_accession":[]},"is_claimable":false,"name":"Nanobody-Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo.","description":"Prostate cancer (PCa) ranks as the fifth leading cause of cancer-related deaths among men worldwide. In 10-20% of the cases, PCa progresses to an incurable, castration-resistant stage. Castration-resistant PCa cells often overexpress prostate-specific membrane antigen (PSMA), a membrane protein that may serve as their Achilles' heel. Over the past decades, RNA-based therapeutics have emerged as promising treatments for a vast array of diseases, including cancer. In this study, with the ultimate goal of developing a targeted therapy for PCa, lipid nanoparticles (LNPs) are decorated with an anti-PSMA nanobody using click chemistry with a PEG-lipid. Direct stochastic optical reconstruction microscopy (dSTORM) and cluster analysis confirm the presence of at least one nanobody on the surface of","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T14:39:08.019Z","creation":"2026-05-29T03:05:30.508Z"},"accession":"S-EPMC12447046","cross_references":{"pubmed":["40613352"],"doi":["10.1002/adhm.202500605"]}}